This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Geron Corporation (NASDAQ:GERN) today announced that it will host a live webcast of the analyst and investor meeting on its cell therapy programs being held in New York from 12:15 p.m. to 1:30 p.m. EDT on Tuesday, April 19, 2011.
Members of Geron’s cell therapy management and team including, Jane Lebkowski, Ph.D., SVP, Chief Scientific Officer; Katharine Spink, Ph.D., SVP, Program Operations; Melanie Nallicheri, SVP Corporate Development; Edward Wirth, M.D., Ph.D., Medical Director; and Anthony Davies, Ph.D., VP, Product Development, will present the company’s cell therapy products derived from its human embryonic stem cell technology platform. Products in development include GRNOPC1 for spinal cord injury, GRNCM1 for heart failure and acute myocardial infarction, GRNVAC2 for cellular immunotherapy, GRNIC1 for diabetes and GRNCHND1 for cartilage repair.
The webcast for the live audio and slide presentation will be available at
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=67323&eventID=3917725. The presentation will be archived for replay and available at the same address one hour after conclusion of the live event for a period of 30 days. It is recommended that listeners log on 15 minutes early in order to register and download any necessary software.
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the blood-brain barrier. The company is developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system (CNS) disorders, heart failure, diabetes and osteoarthritis, and has initiated a Phase 1 clinical trial in spinal cord injury. For more information about Geron, visit